The artificial cornea and corneal implant market in the world were dominated by North America. In North America, the market is well-established, and the US dominates it there. The significant market share of North America is primarily explained by the region’s developed healthcare infrastructure, increased adoption of sophisticated healthcare technology, higher spending power among end users of ophthalmic equipment, and a sizable number of corneal implant producers.
New Delhi, Sept. 05, 2022 (GLOBE NEWSWIRE) — The aging population, increased incidence of eye diseases, government initiatives to lessen visual impairment, and the rising prevalence of eye diseases are the main factors driving the Global Artificial Cornea and Corneal Implant Market.
A recent study conducted by the strategic consulting and market research firm, BlueWeave Consulting, revealed that the Global Artificial Cornea and Corneal Implant Market was worth USD 397.5 million in the year 2021. The market is projected to grow at a CAGR of 12%, earning revenues of around USD 863.7 million by the end of 2028. The Global Artificial Cornea and Corneal Implant Market are booming because the willingness of the consumer to spend money on eye care is credited with driving the expansion in the artificial cornea implant market. Additionally, the main driver of the market’s growth is the rise in ophthalmic illnesses such as keratoconus, Fuchs dystrophy, and viral keratitis. In addition, rising healthcare costs for eye treatment in emerging nations are fueling the expansion of the artificial cornea implant market globally. Additionally, the market can expand as a result of factors including the rise in surgical procedures and the demand for innovative treatment methods. The development of the global artificial cornea implant market, however, is threatened by the high cost of cornea implant surgeries. Additionally, complications from corneal procedures hinder the widespread use of corneal implants.
Eye Diseases Are Increasingly Common
The global population of persons suffering from serious eye problems is growing, and vision loss is becoming a major public health concern. The rising prevalence of chronic diseases such as diabetes and hypertension, as well as the aging population, have all contributed to an increase in the prevalence of eye diseases such as diabetic retinopathy and ocular hypertension (glaucoma). The number of blind or low-vision people is likewise predicted to climb dramatically. According to the Royal National Institute of Blind People (RNIB), over 2 million people in the United Kingdom suffered from sight loss in 2013, with that number expected to climb to 4.1 million by 2050. The globe now, there are 146 million cases of trachoma, of which 10 million have trichiasis and need surgery to prevent corneal blindness, and 4.9 million have trachomatous corneal scarring that has caused them to become completely blind. This results in offering lucrative opportunities for the Global Artificial Cornea and Corneal Implant Market during the forecast period (2022-2028).
Request for Sample Report @ https://www.blueweaveconsulting.com/report/artificial-cornea-and-corneal-implant-market/report-sample
Lack of Corneal Donors
There is an urgent need for corneal donors because around 10 million people worldwide require corneal transplants. Because of a significant lack of donor corneas, there is a more than six-month waiting list for corneal transplants among those with corneal blindness in densely populated countries like India. About 1 million Americans and 6.8 million persons in the country, respectively, suffer visual problems in both eyes as a result of corneal diseases. By the end of 2020, 10.6 million cases of unilateral corneal blindness were expected to occur in India. In 2019, there were about 120,000 cases of corneal blindness. Although the country needs roughly 250,000 corneas annually, only about 25,000 are donated. Given the significant burden of corneal blindness and the scarcity of corneal donors, manufacturers of corneal implants should have significant development potential.
Challenges: Insufficient Ophthalmologists
Ophthalmologists are still in great demand, although their numbers have not grown as quickly as the global population. This is especially clear in emerging nations. In India, for instance, there is one ophthalmologist for every 107,000 people, compared to one for every 15,800 in the US. While some locations (mostly urban centers) have ratios of 1:9,000, other others have ratios as low as 1:608,000. The average number of ophthalmologists per million inhabitants varies depending on the country’s level of economic development, from nine per million on average in low-income nations to 79 per million on average in high-income nations. There were more than 100 ophthalmologists per million persons in just 18 countries (Source: World Bank).
Please Visit the Press Release: https://www.blueweaveconsulting.com/press-release/global-artificial-cornea-and-corneal-implant-market-to-grow-at-a-cagr-of-12-until-2028
Global Artificial Cornea and Corneal Implant Market – By End-User
Based on end-user, the Global Artificial Cornea and Corneal Implant Market is segmented into Hospitals, Specialty Clinics, Ambulatory Surgical Centers, and Others. During the projected period, the category for specialty clinics and ASCs is anticipated to have the greatest CAGR. The decline in in-patient surgeries and the rise in demand for minimally invasive procedures are both factors contributing to this segment’s growth. Concerns about hospital-acquired infections and patient preferences for effective treatment are further fostering the expansion of this market.
Impact of COVID-19 on Global Artificial Cornea and Corneal Implant Market
Due to lockdowns and other restrictions put in place to stop the COVID-19 epidemic, there has been a considerable decrease in the number of patient visits to clinics in the first and second quarters of 2020. As a result, fewer elective eye procedures were performed each week in hospitals and clinics during that time. The number of elective procedures has decreased from 200 surgeries per week to just ten surgeries per week, according to the Ophthalmology Times story. Additionally, the frequency of patient appointments to examination centers has been canceled by 15% in nations like the US. The coronavirus disease (COVID-19) pandemic caused a large loss in patient volume for ophthalmology, according to the same publication. According to estimates, the number of patients seeking glaucoma treatment decreased by 88% and those seeking cataract surgery by 97%. Government programs assisted numerous practices during this time, including Paycheck Protection Program loans, which enabled the ophthalmology sector to successfully continue operations
The leading market players in the Global Artificial Cornea and Corneal Implant Market are AJL Ophthalmic, CorneaGen Inc, Addition Technology Inc, LinkoCare Life Science AB, Presbia Plc, Mediphacos, Aurolab, Cornea Biosciences, Dioptex GmbH, EyeYon Medical, Massachusetts Eye and Ear, Florida Lions Eye Bank, and other prominent players.
The Global Artificial Cornea and Corneal Implant Market is highly fragmented with the presence of several manufacturing companies in the country. The market leaders retain their supremacy by spending on research and development, incorporating cutting-edge technology into their goods, and releasing upgraded items for customers. Various tactics, including strategic alliances, agreements, mergers, and partnerships, are used.
Don’t miss the business opportunity in the Global Artificial Cornea and Corneal Implant Market. Consult our analysts to gain crucial insights and facilitate your business growth.
The in-depth analysis of the report provides information about growth potential, upcoming trends, and statistics of the Global Artificial Cornea and Corneal Implant Market. It also highlights the factors driving forecasts of total market size. The report promises to provide recent technology trends in the Global Artificial Cornea and Corneal Implant Market and industry insights to help decision-makers make sound strategic decisions. Furthermore, the report also analyzes the growth drivers, challenges, and competitive dynamics of the market.
In June 2020, AJL Ophthalmic (Spain) received CE Mark approval for ENDO-K PRO. Product approval will enable the company to provide its portfolio to end users.
Scope of the Report
Historical data – 2018-2021
Base Year – 2021
Forecast – 2022 – 2028
Revenue in USD Billion
By Type, By Transplant Type, By Disease, By End User
AJL Ophthalmic, CorneaGen Inc, Addition Technology Inc, LinkoCare Life Science AB, Presbia Plc, Mediphacos, Aurolab, Cornea Biosciences, Dioptex GmbH, EyeYon Medical, Massachusetts Eye and Ear, Florida Lions Eye Bank, and other prominent players.
By Transplant Type
By Disease Indication
Ambulatory Surgical Centers
Middle East and Africa
Please Find Below Some Related Reports:
Clinical Chemistry Analyzers Market – Global Industry Size, Share, Trend Analysis and Forecast Report, 2018-2028
Urinary Catheters Market – Global Industry Size, Share, Trend Analysis and Forecast Report, 2018-2028
Peptide and Anticoagulant Drugs Market- Global Industry Size, Share, Trend Analysis and Forecast Report, 2018-2028
Medical Tapes and Bandages Market- Global Industry Size, Share, Trend Analysis and Forecast Report, 2018-2028
Interventional Radiology Products Market- Global Industry Size, Share, Trend Analysis and Forecast Report, 2018-2028
BlueWeave Consulting provides comprehensive Market Intelligence (MI) Solutions to businesses regarding various products and services online and offline. We offer all-inclusive market research reports by analyzing both qualitative and quantitative data to boost the performance of your business solutions. BWC has built its reputation from the scratch by delivering quality inputs and nourishing long-lasting relationships with its clients. We are one of the promising digital MI solutions companies providing agile assistance to make your business endeavors successful.
BlueWeave Consulting & Research Pvt. Ltd
+1 866 658 6826 | +1 425 320 4776 | +44 1865 60 0662
CVS Health Corp on Monday agreed to buy home healthcare services company Signify Health for about $8 billion in cash, a move that will enable one of the largest U.S. healthcare companies to provide further care management to patients in their homes. Healthcare companies like CVS have been expanding beyond managing health and pharmacy benefits with acquisitions of doctors groups and surgical centers in recent years. "We’ve been very clear about what we were looking for in expanding our health services, either be it primary care, provider enablement or in the home, and Signify Health clearly checks off two boxes: into the home and provider enablement," CVS CEO Karen Lynch said in an interview.
One miner warned that domestic resources for lithium, the most critical mineral used for electric vehicle production, may not be sufficient enough to meet some U.S. climate targets.
Cut red tape on fracking to secure energy security, Liz Truss urged London Stock Exchange battles to avoid irrelevance as red tape swamps the City FTSE 100 falls 0.4pc after Liz Truss named PM Lucy Burton: Now is not the time for councils to trial four-day weeks at the taxpayers expense Sign up here for our daily business briefing newsletter
Novavax (NVAX) receives expanded temporary authorization for Nuvaxovid, its COVID-19 vaccine, in Switzerland for adolescents aged 12 to 17 and as a booster in adults aged 18 years and above.
And if you’re behind? It’s OK boomer. There’s still some time to catch up.
OPEC+ unexpectedly agreed to trim production quotas slightly, but the move may have little impact on actual output. Crude oil futures jumped Monday.
In this article we listed the 25 biggest pharmaceutical companies in the world a year ago and then compared their market caps today. Most of the article was written a year ago and discuss what hedge funds thought about those companies at that time. The biggest loser in the list is probably Moderna (MRNA) which […]
Is there a recommended strategy for taking required withdrawals from retirement savings in this horrible market? Unfortunately, the Internal Revenue Service makes me sell stocks at the worst time. As it happens, the timing of these questions works well: Many retirees wait until late in the year to withdraw the necessary funds from IRAs and the like.
The deepening energy crisis following the closure of the Nord Stream 1 gas pipeline has sent equities and the euro tumbling.
A promising cancer drug combo from Bristol Myers Squibb is months away from being approved in the European Union to treat patients with a form of skin cancer.
(Bloomberg) — Most Read from BloombergAmazon Closes, Abandons Plans for Dozens of US WarehousesRussia Privately Warns of Deep and Prolonged Economic DamageWorld’s Deadliest Roads in Focus After Billionaire’s Fatal CrashNASA’s Artemis Rocket Is a Gigantic Waste of MoneyCalifornia Declares Grid Emergency as Odds of Blackouts RiseThe first OPEC+ oil supply cut in more than a year shows the group is serious about managing global crude markets and willing to take preemptive action, said group leader
Some recalls involving Ford's Mustang Mach E along with Rivian's R1T pickup truck and R1S SUV were listed on NHTSA's website Monday.
Investors who proclaim their attachment to ESG should address longstanding worker concerns first, says bottling plant worker Cesar Moreira.
There's a raging debate around the future of commodity prices, impacting the outlook for these three companies.
(Bloomberg) — Taiwanese battery maker ProLogium Technology Co. is considering the UK among the potential sites for an $8 billion factory that would build a promising but unproven new generation of cells for electric vehicles.Most Read from BloombergAmazon Closes, Abandons Plans for Dozens of US WarehousesRussia Privately Warns of Deep and Prolonged Economic DamageWorld’s Deadliest Roads in Focus After Billionaire’s Fatal CrashNASA’s Artemis Rocket Is a Gigantic Waste of MoneyCalifornia Declares
Ischemic stroke occurs when a blood clot blocks the flow of blood through a narrow artery to the brain. This triggers a major medical emergency as the brain quickly becomes deprived of necessary oxygen and nutrients. While there are many factors which can contribute to your stroke risk, researchers have recently found that one somewhat unexpected factor—your blood type—could make you 16 percent more likely to experience a stroke before the age of 60. Read on to learn whether you're at heightened
The oil producing cartel has agreed to cut output targets just days after U.S.-led agreement to establish a buyer’s alliance seeking price-setting power over Russian crude.
South Carolina currently bans abortion after 20 weeks
(Bloomberg) — Europe’s energy crisis is getting worse, piling pressure on the commodities industries that provide building blocks for the continent’s economy.Most Read from BloombergAmazon Closes, Abandons Plans for Dozens of US WarehousesRussia Privately Warns of Deep and Prolonged Economic DamageWorld’s Deadliest Roads in Focus After Billionaire’s Fatal CrashNASA’s Artemis Rocket Is a Gigantic Waste of MoneyCalifornia Declares Grid Emergency as Odds of Blackouts RisePower- and gas-intensive s
A shake-up in the labour market gives the upper hand to job applicants